Cash flow Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Delayed Nyse Other stock markets 20:56:31 11/09/2024 BST			5-day change	1st Jan Change
16.91 ^USD	+1.38%		+3.37%	-11.68%

09-04	Transcript : Arcus Biosciences, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 04:50 PM
08-27	Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital	MT

893.4jepmtpVPuayC8oOiNaSbWT1TYDnUrA8H1bfDSqWg-Q.qnPC-6s4dtLeM49L3q7XOgyRG7eAPvFeZhWcS0z57YaOYJjguyFXi_9MqQ

Published financial data: ARCUS BIOSCIENCES, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	15M	77.52M	383M	112M	117M
Total Revenues	15M	77.52M	383M	112M	117M
Cost of Goods Sold, Total	78.48M	159M	256M	288M	340M
Gross Profit	-63.48M	-81.83M	127M	-176M	-223M
Selling General & Admin Expenses, Total	25.23M	42.4M	72.29M	104M	117M
R&D Expenses	-	-	-	-	-
Other Operating Expenses, Total	25.23M	42.4M	72.29M	104M	117M
Operating Income	-88.71M	-124M	54.25M	-280M	-340M
Interest Expense, Total	-	-	-260K	-2M	-2M
Interest And Investment Income	5.2M	1.38M	657K	16M	41M
Net Interest Expenses	5.2M	1.38M	397K	14M	39M
Income (Loss) On Equity Invest.	-1.2M	-613K	-	-	-
EBT, Excl. Unusual Items	-84.71M	-123M	54.64M	-266M	-301M
Gain (Loss) On Sale Of Investments	-	613K	-	-	-
EBT, Incl. Unusual Items	-84.71M	-123M	54.64M	-266M	-301M
Income Tax Expense	-	-	1.82M	1M	6M
Earnings From Continuing Operations	-84.71M	-123M	52.83M	-267M	-307M
Net Income to Company	-84.71M	-123M	52.83M	-267M	-307M
Net Income - (IS)	-84.71M	-123M	52.83M	-267M	-307M
Net Income to Common Incl Extra Items	-84.71M	-123M	52.83M	-267M	-307M
Net Income to Common Excl. Extra Items	-84.71M	-123M	52.83M	-267M	-307M
Per Share Items
Net EPS - Basic	-1.93	-2.24	0.76	-3.71	-4.15
Basic EPS - Continuing Operations	-1.93	-2.24	0.76	-3.71	-4.15
Basic Weighted Average Shares Outstanding	43.83M	54.79M	69.35M	72M	74M
Net EPS - Diluted	-1.93	-2.24	0.71	-3.71	-4.15
Diluted EPS - Continuing Operations	-1.93	-2.24	0.71	-3.71	-4.15
Diluted Weighted Average Shares Outstanding	43.83M	54.79M	73.97M	72M	74M
Normalized Basic EPS	-1.21	-1.41	0.49	-2.31	-2.54
Normalized Diluted EPS	-1.21	-1.41	0.46	-2.31	-2.54
Supplemental Items
EBITDA	-85.13M	-121M	58.09M	-274M	-332M
EBITA	-88.71M	-124M	54.25M	-280M	-340M
EBIT	-88.71M	-124M	54.25M	-280M	-340M
EBITDAR	-83.53M	-118M	65.49M	-256M	-315M
Total Revenues (As Reported)	-	77.52M	383M	112M	117M
Effective Tax Rate - (Ratio)	-	-	3.32	-0.38	-1.99
Current Domestic Taxes	-	-	-	1M	6M
Total Current Taxes	-	-	-	1M	6M
Normalized Net Income	-52.94M	-77.17M	34.15M	-166M	-188M
Supplemental Operating Expense Items
General and Administrative Expenses	25.23M	42.4M	72.29M	104M	100M
Research And Development Expense From Footnotes	78.48M	159M	256M	288M	340M
Net Rental Expense, Total	1.6M	2.9M	7.4M	18M	17M
Imputed Operating Lease Interest Expense	-	-	233K	2.43M	2.26M
Imputed Operating Lease Depreciation	-	-	7.17M	15.57M	14.74M
Stock-Based Comp., COGS (Total)	4.15M	11.2M	28.3M	33M	35M
Stock-Based Comp., R&D Exp. (Total)	-	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	4.83M	10.63M	26.23M	32M	38M
Total Stock-Based Compensation	8.98M	21.82M	54.53M	65M	73M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	57.94M	173M	148M	206M	127M
Short Term Investments	130M	555M	351M	803M	632M
Total Cash And Short Term Investments	188M	729M	499M	1.01B	759M
Accounts Receivable, Total	132K	1.05M	745M	39M	38M
Other Receivables	-	649K	10.61M	4M	4M
Total Receivables	132K	1.7M	755M	43M	42M
Prepaid Expenses	4.3M	4.47M	6.34M	14M	30M
Other Current Assets, Total	-	1M	900K	1M	-
Total Current Assets	193M	736M	1.26B	1.07B	831M
Gross Property Plant And Equipment	20.55M	38.92M	155M	158M	174M
Accumulated Depreciation	-11.22M	-15.33M	-17.73M	-23M	-31M
Net Property Plant And Equipment	9.33M	23.59M	137M	135M	143M
Long-term Investments	-	6.44M	182M	129M	107M
Deferred Charges Long-Term	-	3.2M	4M	3M	-
Other Long-Term Assets, Total	1.08M	3.25M	6.74M	11M	14M
Total Assets	203M	772M	1.59B	1.34B	1.1B
Liabilities
Accounts Payable, Total	4.7M	15.68M	10.26M	20M	17M
Accrued Expenses, Total	9.52M	27.85M	51.95M	70M	62M
Current Portion of Leases	-	2.87M	-	3M	11M
Current Income Taxes Payable	-	-	1.82M	-	-
Unearned Revenue Current, Total	7M	74.57M	102M	97M	91M
Other Current Liabilities	1.48M	699K	52K	3M	3M
Total Current Liabilities	22.71M	122M	166M	193M	184M
Long-Term Leases	-	15.24M	117M	117M	110M
Unearned Revenue Non Current	12.02M	133M	462M	355M	307M
Other Non Current Liabilities	4.54M	546K	5.26M	23M	32M
Total Liabilities	39.27M	270M	750M	688M	633M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	4K	6K	7K	1.21B	1.31B
Additional Paid In Capital	369M	830M	1.12B	-	-
Retained Earnings	-205M	-328M	-275M	-542M	-849M
Comprehensive Income and Other	64K	44K	-1.26M	-7M	-
Total Common Equity	164M	502M	841M	657M	462M
Total Equity	164M	502M	841M	657M	462M
Total Liabilities And Equity	203M	772M	1.59B	1.34B	1.1B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	45.97M	70.88M	71.06M	73.01M	90.86M
ECS Total Common Shares Outstanding	45.93M	65.11M	70.78M	72.9M	75.5M
Book Value / Share	3.57	7.71	11.89	9.01	6.12
Tangible Book Value	164M	502M	841M	657M	462M
Tangible Book Value Per Share	3.57	7.71	11.89	9.01	6.12
Total Debt	0	18.11M	117M	120M	121M
Net Debt	-188M	-711M	-382M	-1.02B	-745M
Debt Equivalent Oper. Leases	12.8M	23.2M	59.2M	144M	136M
Equity Method Investments, Total	-	-	-	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	9.33M	11.42M	15.78M	20M	27M
Full Time Employees	139	236	366	500	577

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	-84.71M	-123M	52.83M	-267M	-307M
Depreciation & Amortization - CF	3.58M	4.19M	3.84M	6M	8M
Depreciation & Amortization, Total	3.58M	4.19M	3.84M	6M	8M
(Gain) Loss on Sale of Investments - (CF)	-2.64M	-46K	4.77M	-	-19M
(Income) Loss On Equity Investments - (CF)	1.2M	-	-	-	-
Stock-Based Compensation (CF)	8.98M	21.82M	54.53M	65M	73M
Other Operating Activities, Total	-	-	3.47M	11M	10M
Change In Accounts Receivable	-132K	-917K	-17.05M	704M	15M
Change In Accounts Payable	1.73M	9.27M	-4.77M	8M	-1M
Change in Unearned Revenues	-2M	178M	-368M	-112M	-68M
Change in Other Net Operating Assets	531K	21.32M	14.08M	23M	-17M
Cash from Operations	-73.46M	111M	-256M	438M	-306M
Capital Expenditure	-1.92M	-3.06M	-26.08M	-6M	-24M
Sale (Purchase) of Intangible assets	-	-	-	-6M	-
Investment in Marketable and Equity Securities, Total	61.14M	-431M	22.21M	-404M	218M
Other Investing Activities, Total	-	-	-	3M	-
Cash from Investing	59.21M	-434M	-3.87M	-413M	194M
Issuance of Common Stock	1.22M	439M	232M	23M	33M
Repurchase of Common Stock	-94K	-54K	-6K	-	-
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-	-	5M	10M	-
Cash from Financing	1.12M	439M	237M	33M	33M
Net Change in Cash	-13.13M	115M	-22.7M	58M	-79M
Supplemental Items
Cash Income Tax Paid (Refund)	-	-	-	3M	5M
Levered Free Cash Flow	-41.07M	38.68M	-645M	612M	-188M
Unlevered Free Cash Flow	-41.07M	38.68M	-645M	613M	-186M
Change In Net Working Capital	-3.74M	-93.36M	711M	-729M	31M

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	-23.2	-15.92	2.87	-11.92	-17.42
Return on Total Capital	-27.81	-22.7	4.59	-20.16	-31.25
Return On Equity %	-42.48	-36.89	7.86	-35.62	-54.87
Return on Common Equity	-42.48	-36.89	7.86	-35.62	-54.87
Margin Analysis
Gross Profit Margin %	-423.21	-105.57	33.05	-157.14	-190.6
SG&A Margin	168.19	54.7	18.88	92.86	100
EBITDA Margin %	-567.54	-156.21	15.17	-244.64	-283.76
EBITA Margin %	-591.39	-160.27	14.17	-250	-290.6
EBIT Margin %	-591.39	-160.27	14.17	-250	-290.6
Income From Continuing Operations Margin %	-564.73	-158.49	13.8	-238.39	-262.39
Net Income Margin %	-564.73	-158.49	13.8	-238.39	-262.39
Net Avail. For Common Margin %	-564.73	-158.49	13.8	-238.39	-262.39
Normalized Net Income Margin	-352.96	-99.55	8.92	-148.44	-160.79
Levered Free Cash Flow Margin	-273.79	49.89	-168.41	546.21	-160.47
Unlevered Free Cash Flow Margin	-273.79	49.89	-168.37	547.32	-159.4
Asset Turnover
Asset Turnover	0.06	0.16	0.32	0.08	0.1
Fixed Assets Turnover	1.47	4.71	4.76	0.82	0.84
Receivables Turnover (Average Receivables)	-	131.27	1.03	0.29	3.04
Short Term Liquidity
Current Ratio	8.49	6.05	7.6	5.53	4.52
Quick Ratio	8.3	6	7.55	5.45	4.35
Operating Cash Flow to Current Liabilities	-3.24	0.91	-1.54	2.27	-1.66
Days Sales Outstanding (Average Receivables)	-	2.79	355.41	1.28K	120.11
Average Days Payable Outstanding	18.15	23.41	18.47	19.01	19.86
Long Term Solvency
Total Debt/Equity	-	3.61	13.89	18.26	26.19
Total Debt / Total Capital	-	3.48	12.2	15.44	20.75
LT Debt/Equity	-	3.03	13.89	17.81	23.81
Long-Term Debt / Total Capital	-	2.93	12.2	15.06	18.87
Total Liabilities / Total Assets	19.33	34.96	47.14	51.15	57.81
EBIT / Interest Expense	-	-	208.65	-140	-170
EBITDA / Interest Expense	-	-	251.89	-128	-157.5
(EBITDA - Capex) / Interest Expense	-	-	151.59	-131	-169.5
Total Debt / EBITDA	-	-0.15	1.78	-0.47	-0.38
Net Debt / EBITDA	2.21	6.01	-5.84	3.98	2.37
Total Debt / (EBITDA - Capex)	-	-0.15	2.97	-0.46	-0.36
Net Debt / (EBITDA - Capex)	2.16	5.86	-9.7	3.89	2.2
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	79.58	416.78	393.93	-70.76	4.46
Gross Profit, 1 Yr. Growth %	53.73	28.91	-254.63	-239.68	26.7
EBITDA, 1 Yr. Growth %	66.29	42.23	-147.97	-572.41	21.17
EBITA, 1 Yr. Growth %	61.7	40.05	-143.67	-618.52	21.43
EBIT, 1 Yr. Growth %	61.7	40.05	-143.67	-618.52	21.43
Earnings From Cont. Operations, 1 Yr. Growth %	70.81	45.03	-143	-603.77	14.98
Net Income, 1 Yr. Growth %	70.81	45.03	-143	-603.77	14.98
Normalized Net Income, 1 Yr. Growth %	66.68	45.76	-144.26	-583.64	13.16
Diluted EPS Before Extra, 1 Yr. Growth %	34.92	16.02	-131.66	-622.54	11.86
Accounts Receivable, 1 Yr. Growth %	-	694.7	70.88K	-94.77	-2.56
Net Property, Plant and Equip., 1 Yr. Growth %	-16	152.82	482.6	-1.46	5.93
Total Assets, 1 Yr. Growth %	-26.12	280.23	106.13	-15.52	-18.59
Tangible Book Value, 1 Yr. Growth %	-30.26	206.58	67.52	-21.97	-29.68
Common Equity, 1 Yr. Growth %	-30.26	206.58	67.52	-21.97	-29.68
Cash From Operations, 1 Yr. Growth %	70.86	-251.33	-330.43	-271.09	-169.86
Capital Expenditures, 1 Yr. Growth %	-48.57	58.7	753.62	-76.92	300
Levered Free Cash Flow, 1 Yr. Growth %	49.23	-194.17	-1.69K	-194.88	-130.69
Unlevered Free Cash Flow, 1 Yr. Growth %	49.23	-194.17	-1.69K	-195.08	-130.42
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	225.82	204.63	405.23	19.83	-44.73
Gross Profit, 2 Yr. CAGR %	17.72	40.77	41.18	47.41	33.04
EBITDA, 2 Yr. CAGR %	29.42	53.79	-17.39	50.48	139.25
EBITA, 2 Yr. CAGR %	28.84	50.49	-21.8	50.27	150.92
EBIT, 2 Yr. CAGR %	28.84	50.49	-21.8	50.27	150.92
Earnings From Cont. Operations, 2 Yr. CAGR %	26.33	57.39	-21.03	47.33	140.68
Net Income, 2 Yr. CAGR %	26.33	57.39	-21.03	47.33	140.68
Normalized Net Income, 2 Yr. CAGR %	26.33	55.87	-19.68	47.06	133.94
Diluted EPS Before Extra, 2 Yr. CAGR %	-74.2	25.11	-39.39	28.57	141.77
Accounts Receivable, 2 Yr. CAGR %	-	-	7.41K	509.74	-77.42
Net Property, Plant and Equip., 2 Yr. CAGR %	-8.85	45.73	283.79	139.23	2.17
Total Assets, 2 Yr. CAGR %	3.26	67.6	179.96	31.97	-17.07
Tangible Book Value, 2 Yr. CAGR %	50.51	46.22	126.62	14.37	-25.93
Common Equity, 2 Yr. CAGR %	50.51	46.22	126.62	14.37	-25.93
Cash From Operations, 2 Yr. CAGR %	71.22	60.8	86.74	98.64	9.33
Capital Expenditures, 2 Yr. CAGR %	-40.91	-9.66	268.06	41.42	-3.92
Levered Free Cash Flow, 2 Yr. CAGR %	19.01	18.55	296.24	287.56	-46.04
Unlevered Free Cash Flow, 2 Yr. CAGR %	19.01	18.55	296.19	287.95	-46.22
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %